P&G to acquire supplement brand Thorne for $3.8 billion
Procter & Gamble (P&G) said it will acquire supplement brand Thorne for $3.8 billion from L Catterton’s Flagship Fund, with closing expected later this year subject to regulatory approvals. CNBC reported Thorne revenue exceeded $500 million in 2025. P&G said the deal expands its health and wellness portfolio; P&G shares rose about 1% Tuesday.
How this was made
The 30-second read
Why it matters
A $3.8B acquisition of a premium, science-backed supplement brand with 2025 revenue above $500M is a material strategic step that can shift investor expectations for growth in health and wellness.
Market read
Traders can price deal risk and strategic value for PG based on the disclosed purchase price and the stated closing conditions.
What to watch
The article does not specify financing structure, expected synergies, or regulatory timeline, which are key drivers of post-announcement valuation.
Background
P&G already owns health and wellness brands including Metamucil, Align Probiotic, New Chapter, Oral-B, and Vicks, and is adding Thorne to its Personal Health Care business.
Ticker impact
P&G will pay $3.8 billion to acquire Thorne, expanding its health and wellness portfolio and subject to regulatory approvals.
Bullish bias near-term on deal enthusiasm, with follow-through dependent on regulatory clearance and deal financing details.
The article provides the headline deal price, buyer, seller, and expected closing window, which are the key tradable inputs for M&A risk and valuation.
Market effects
Reinforces consolidation in vitamins, minerals, and supplements, potentially raising competitive pressure on other premium wellness brands.
Limited direct regional impact stated, but US consumer health M&A could influence broader North American consumer staples sentiment.
Signals global CPG players’ continued appetite for health and wellness assets, which can affect cross-border deal expectations.
Counterpoint
Deal value may be partially offset by integration risk and potential regulatory friction, limiting upside beyond initial M&A enthusiasm.
Key entities
- acquirerP&G
Announced it will pay $3.8B to acquire Thorne, expanding its Personal Health Care business.
- targetThorne
Premium supplement brand with annual revenue above $500M in 2025, expected to be acquired later this year.
- sellerL Catterton's Flagship Fund
Current owner selling Thorne to P&G; Reuters cited a large return for the fund.
